In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over Ibrutinib - especially for 17p and patients with heart risks.
Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana Farber, updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American Society of Hematology (ASH) Annual Meeting, including the results of the ALPINE study and the new BTK inhibitors.
-
Len
Written by
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
I believe she is indicating that the early / young data shows the strongest benefit to those high risk patients. It will take more time to see if the future data and other studies show a strong or moderate benefit to untreated or other genetic profiles.
-
The latest NCCN guidelines recommend Zanubrutinib for all CLL patients - see:
Good morning. Any insight into what's the hold up at FDA in US? Secondly, is it reasonable to assume Zanubrutinib would penetrate the blood brain barrier like acali and ibrutinib? Thank you
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.